2 studies found for:    23724867 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Active, not recruiting Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma
Condition: Malignant Melanoma
Interventions: Drug: BMS-936558 (MDX1106-04);   Drug: Ipilimumab
2 Not yet recruiting Phase III Open Label First Line Therapy Study of MEDI 4736 With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC).
Condition: Non-Small-Cell Lung Carcinoma (NSCLC)
Interventions: Biological: MEDI4736;   Biological: MEDI4736+Tremelimumab;   Drug: Paclitaxel + Carboplatin;   Drug: Gemcitabine + Cisplatin;   Drug: Gemcitabine + Carboplatin;   Drug: Pemetrexed + Cisplatin;   Drug: Pemetrexed + Carboplatin;   Biological: Tremelimumab

Indicates status has not been verified in more than two years